Abstract:Abstract BACKGROUND Tumor Treating Fields (TTFields) are electric fields that disrupt cellular processes critical for cancer cell viability and tumor progression, ultimately leading to cell death. TTFields therapy concurrent with maintenance temozolomide (TMZ) is approved for treatment of newly-diagnosed glioblastoma (GBM). Recently, benefit was demonstrated in patients with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation for the combination of TMZ with lomustine (CCNU). The addition of adjuvant TTFields to this treatment regimen further improved patient outcomes, leading to a CE mark. The current study aimed to elucidate the mechanism underlying the benefit of this treatment protocol by utilizing GBM cell lines with different MGMT expression status. MATERIAL AND METHODS Human GBM cell lines with different MGMT promoter methylation status [LN-18 (unmethylated MGMT promoter), U-118 MG (partially methylated MGMT promoter), and U-87 MG and LN-229 (methylated MGMT promoter)] were examined for MGMT expression levels. Next, the cells were treated with TTFields (intensity of 0.83 V/cm RMS; frequency of 200 kHz) using the inovitro system. Cell count and colony formation were employed to detect the effectiveness of TTFields concomitant with TMZ and/or CCNU. Western blot allowed the detection of expression levels of DNA repair proteins in control versus TTFields-treated cells. RESULTS The cell lines displayed comparable responses to TTFields and CCNU, while they differed in sensitivity to TMZ according to MGMT expression status. TTFields concomitant with TMZ displayed an additive effect, irrespective of MGMT expression levels. The effect of concomitant TTFields with CCNU was additive in MGMT-expressing cell lines, whereas it trended toward synergy in MGMT-non-expressing cell lines. Expression of proteins from the Fanconi Anemia (FA)-BRCA pathway for DNA repair was downregulated following TTFields application. TTFields concurrent with both TMZ and CCNU provided higher efficacy relative to TMZ plus CCNU or TTFields apart, with additivity in MGMT-expressing cell lines and a tendency toward synergy in MGMT-non-expressing cell lines. CONCLUSION The results support the clinical benefit demonstrated for concomitant TTFields with TMZ plus CCNU, showing that the efficacy of TMZ and CCNU may be enhanced by TTFields, with synergism seen for the latter case in cells not expressing MGMT. The BRCAness state induced by TTFields rationalizes this, as in the absence of MGMT DNA damage induced by CCNU requires the FA-BRCA pathway for repair.

A novel approach to investigate the combinatorial effects of TLK1 (Tousled-Like Kinase1) inhibitors with Temozolomide for glioblastoma therapy

Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma

Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma

EXTH-62. TG02, A NOVEL TARGETING OF TRANSCRIPTION AND METABOLISM IN GLIOBLASTOMA

Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres

Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells

Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines

A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance

Synergistic antitumor effects of Phlorizin and Temozolomide in glioblastoma: Mechanistic insights and molecular targeting

Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells

MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives

Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.

Exth-23. New Dna-Crosslinking Chemotherapy Is Effective Against Post-Temozolomide Mismatch Repair-Deficient Patient-Derived Hypermutant Gliomas

Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma

PLGA-based dual-loaded nanoformulation of DIM and TMZ - An advanced clinical strategy for brain cancer treatment in a combinatorial approach

Synergism of d-limonene and temozolomide on migratory and apoptotic behaviors of human glioblastoma cell lines

Considering the Experimental Use of Temozolomide in Glioblastoma Research

P10.06.B APPLYING TUMOR TREATING FIELDS (TTFIELDS) FOR ENHANCEMENT OF TEMOZOLOMIDE AND LOMUSTINE EFFICACY IN GLIOBLASTOMA CELL LINES

KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis